Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/jspui/handle/10553/73252
Title: KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Authors: Rodríguez Abreu, D.
Garassino, M. C.
Esteban, E.
Speranza, G.
Felip, E.
Domine, M.
Hochmair, M. J.
Powell, S.
Cheng, S. Y-S.
Bischoff, H. G.
Peled, N.
Hui, R.
Reck, M.
Garon, E. B.
Boyer, M.
Grossi, F.
Jennens, R.
Yang, J.
Pietanza, M. C.
Gadgeel, S.
UNESCO Clasification: 320101 Oncología
Issue Date: 2018
Journal: Annals of Oncology 
Conference: European-Society-for-Medical-Oncology Asia Congress 
URI: https://accedacris.ulpgc.es/handle/10553/73252
ISSN: 0923-7534
Source: Annals of Oncology [ISSN 0923-7534], v. 29 (sup. 9), p. 164, Abstract 532P, (Noviembre 2018)
Appears in Collections:Actas de congresos
Thumbnail
pdf
Adobe PDF (62,49 kB)
Show full item record

WEB OF SCIENCETM
Citations

3
checked on Feb 25, 2024

Page view(s)

185
checked on Jan 16, 2026

Download(s)

233
checked on Jan 16, 2026

Google ScholarTM

Check


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.